Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
Laura Deborah LocatiStefano CavalieriCristiana BergaminiCarlo ResteghiniSalvatore AlfieriGiuseppina CalaresoPaolo BossiFederica PerroneElena TamboriniPasquale QuattroneRoberta GranataDonata GalbiatiFrancesca PlatiniEster OrlandiLuigi MarianiLisa LicitraPublished in: Head & neck (2019)
This trial did not meet its primary endpoint hence axitinib should not be considered for further investigations in SGCs. Safety profile was in line with the scientific literature.